Osmind presented a retrospective comparative study of de-identified electronic health record data in a sample of 8,224 patients with treatment resistant depression treated with IV ketamine and 1,830 patients treated with intranasal esketamine from 800 community psychiatry clinics. IV ketamine patients demonstrated significantly higher rates of remission (OR 1.51; P

LITTLETON, Colo., June 05, 2026 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including obstructive sleep apnea (“OSA”), today announced that it has entered into a binding agreement with its senior, secured lender, Streeterville Capital, LLC (Streeterville) to exchange up to $4.5 million of its outstanding debt into a combination of perpetual, nonconvertible preferred stock and shares of common stock of the Company. In addition, the agreement includes commitments from Streeterville to suspend any calls for repayments of its debt and any sales of Company securities for 90 and 60 days, respectively, from the date the debt-to-equity...

TARRYTOWN, N.Y., June 05, 2026 (GLOBE NEWSWIRE) — Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will participate in a fireside chat at the Oppenheimer 26th Annual Consumer Growth and E-Commerce Conference virtually on Monday, June 8, 2026 at 9:45 a.m. ET. A live webcast of this event will be available at www.prestigeconsumerhealthcare.com under the “Investors” section and the “Events and Presentations” tab, or by using the following link: https://ir.prestigebrands.com/events-presentations/events For those unable to participate during the live webcast, a replay option will be available on the Company’s website following the event. About Prestige Consumer Healthcare Inc. Prestige Consumer Healthcare markets, sells, manufactures and distributes consumer healthcare products to retail outlets...

Surveyed oncologists reported high likelihood to prescribe (6 of 7), citing deep remissions, transplant-bridging potential, biomarker-agnostic use and reduced cardiotoxicity as key drivers Parallel survey of payers shows strong support for Annamycin filling a significant unmet need HOUSTON, June 05, 2026 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced results from an independent market landscape assessment evaluating Annamycin in relapsed/refractory acute myeloid leukemia (R/R AML). The research demonstrated strong physician interest in Annamycin, with oncologists reporting an average likelihood-to-prescribe score of 6 out of 7. Physicians cited Annamycin’s reported complete remission rates, MRD-negative responses, potential to bridge patients to bone marrow transplant,...

NEW YORK, June 05, 2026 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced TelyRx Holdings Inc. (TSX: TELY; OTCQX: TELYF), a vertically integrated, technology-enabled healthcare and pharmacy services company, has qualified to trade on the OTCQX® Best Market. TelyRx Holdings Inc. begins trading today on OTCQX under the symbol “TELYF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com. Trading on the OTCQX Market offers companies efficient, cost-effective access to the U.S. capital markets. For companies listed on a qualified international exchange, streamlined market standards enable them to utilize their home market reporting to make their information available...

Person subject to the notification requirementName: AS InfortarPosition: Person closely associated with the person discharging managerial responsibilities (Ain Hanschmidt, member of the supervisory board) Issuer: AS Tallink GruppLEI: 529900QRMWAKKR3L9W75 Notification type: Initial Notification_____________________________________ Transaction date: 04.06.2026Place of transaction: Nasdaq OMX TallinnInstrument type: ShareISIN: EE3100004466Nature of the transaction: Acquisition Transaction details:(1): Volume: 462,000; Unit price: 0.646 EUR Aggregated transactions:(1): Volume: 462,000; Volume weighted average price: 0.646 EURAnneli SimmInvestor Relations Manager AS Tallink GruppSadama 510111 TallinnE-mail: Anneli.simm@tallink.eePhone: +372 56157170

Person subject to the notification requirementName: AS InfortarPosition: Person closely associated with the person discharging managerial responsibilities (Ain Hanschmidt, member of the supervisory board) Issuer: AS Tallink GruppLEI: 529900QRMWAKKR3L9W75 Notification type: Initial Notification_____________________________________ Transaction date: 04.06.2026Place of transaction: Nasdaq OMX TallinnInstrument type: ShareISIN: EE3100004466Nature of the transaction: Acquisition Transaction details:(1): Volume: 462,000; Unit price: 0.646 EUR Aggregated transactions:(1): Volume: 462,000; Volume weighted average price: 0.646 EUR Anneli SimmInvestor Relations Manager AS Tallink GruppSadama 510111 TallinnE-mail: Anneli.simm@tallink.eePhone: +372 56157170